Location History:
- Jersey City, NY (US) (2019)
- Jersey City, NJ (US) (2020)
Company Filing History:
3 out of 2,405 
1 out of 100 
1 out of 7 Years Active: 2019-2024
Title: Innovations by Steven M. Silverman: A Focus on PRMT5 Inhibitors
Introduction: Steven M. Silverman is a notable inventor based in Jersey City, NJ, whose contributions to the field of medicine include the development of innovative compounds aimed at treating serious health conditions. With one patent to his name, he showcases the potential impact of scientific innovation on therapeutic approaches.
Latest Patents: Steven holds a patent for PRMT5 inhibitors, which are recognized for their usefulness in formulating compounds that can assist in the treatment of cancer, sickle cell disease, and hereditary persistence of fetal hemoglobin (HPFH) mutations. The patent details compounds of Formula (I) along with their pharmaceutically acceptable salts, esters, and prodrugs, along with methods for their synthesis and application, making a significant contribution to pharmacology.
Career Highlights: Throughout his career, Steven M. Silverman has worked with renowned organizations such as Merck Sharp & Dohme Corporation and MSD International GmbH. His roles in these companies reflect his commitment to advancing medical science through research and product development.
Collaborations: Steven's work with major pharmaceutical companies emphasizes the importance of collaboration in the innovation process. By partnering with leading entities in the pharmaceutical industry, he has leveraged resources and expertise to bring his inventive concepts to fruition.
Conclusion: Steven M. Silverman's innovative approach to developing PRMT5 inhibitors represents a significant advancement in the landscape of cancer and genetic mutation therapies. His contributions are a testament to the critical role that inventors play in the ongoing quest for new medical solutions. Through his work, he inspires further research and exploration in the field of pharmaceuticals.